Trial Profile

A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mosunetuzumab (Primary) ; Mosunetuzumab (Primary) ; Polatuzumab vedotin; Tocilizumab
Indications Diffuse large B cell lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Roche

03 Apr 2025 Planned End Date changed from 3 Aug 2025 to 7 Aug 2025.
03 Apr 2025 Planned primary completion date changed from 3 Aug 2025 to 7 Aug 2025.
30 May 2024 Planned primary completion date changed from 4 Feb 2024 to 3 Aug 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com